Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2008 by Capital Medical University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Capital Medical University
ClinicalTrials.gov Identifier:
NCT00815594
First received: December 29, 2008
Last updated: NA
Last verified: December 2008
History: No changes posted

December 29, 2008
December 29, 2008
December 2008
March 2009   (final data collection date for primary outcome measure)
bleb vascular change [ Time Frame: one day, one week, one month ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Bleb Vascularity Change After Subconjunctival Injection Bevacizumab
Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Bleb Vascularity
  • Conjunctival Scarring
Drug: bevacizumab
0.05ml, 1.25mg
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
30
May 2009
March 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Glaucoma patients after trabeculectomy whose bleb is hyperaemia

Exclusion Criteria:

  • Affected eye has normal IOP
  • Not allergic with Avastin
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00815594
2008TR-LX-001
Yes
Wang NingLi, Beiing Tongren hospital
Capital Medical University
Not Provided
Principal Investigator: Liu Xuan, M.D. An ophthalmologist in Tongren hospital
Capital Medical University
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP